{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:20:33Z","timestamp":1792844433773,"version":"4.5.0"},"reference-count":116,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The effects of celecoxib on a broad spectrum of mood disorders and on inflammatory parameters have not yet been comprehensively evaluated. The aim of this study was to systematically summarize the available knowledge on this topic. Data from both preclinical and clinical studies were analyzed, considering the efficacy and safety of celecoxib in the treatment of mood disorders, as well as the correlation of inflammatory parameters with the effect of celecoxib treatment. Forty-four studies were included. We found evidence supporting the antidepressant efficacy of celecoxib in a dose of 400 mg\/day used for 6 weeks as an add-on treatment in major depression (SMD = \u22121.12 [95%Cl: \u22121.71,\u22120.52], p = 0.0002) and mania (SMD = \u22120.82 [95% CI:\u22121.62,\u22120.01], p = 0.05). The antidepressant efficacy of celecoxib in the above dosage used as sole treatment was also confirmed in depressed patients with somatic comorbidity (SMD = \u22121.35 [95% CI:\u22121.95,\u22120.75], p &lt; 0.0001). We found no conclusive evidence for the effectiveness of celecoxib in bipolar depression. Celecoxib at a dose of 400 mg\/d used for up to 12 weeks appeared to be a safe treatment in patients with mood disorders. Although an association between celecoxib response and inflammatory parameters has been found in preclinical studies, this has not been confirmed in clinical trials. Further studies are needed to evaluate the efficacy of celecoxib in bipolar depression, as well as long-term studies evaluating the safety and efficacy of celecoxib in recurrent mood disorders, studies involving treatment-resistant populations, and assessing the association of celecoxib treatment with inflammatory markers.<\/jats:p>","DOI":"10.3390\/jcm12103497","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T01:58:06Z","timestamp":1684288686000},"page":"3497","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9312-2976","authenticated-orcid":false,"given":"Adam","family":"G\u0119dek","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Institute of Psychiatry and Neurology, Sobieskiego 9, 02-957 Warsaw, Poland"},{"name":"Praski Hospital, Aleja Solidarno\u015bci 67, 03-401 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Szular","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Medical University of Warsaw, \u017bwirki i Wigury 61, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8570-4706","authenticated-orcid":false,"given":"Anna Z.","family":"Antosik","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Collegium Medicum, Cardinal Wyszynski University in Warsaw, Woycickiego 1\/3, 01-938 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0642-6075","authenticated-orcid":false,"given":"Pawe\u0142","family":"Mierzejewski","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Psychiatry and Neurology, Sobieskiego 9, 02-957 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-2289","authenticated-orcid":false,"given":"Monika","family":"Dominiak","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Psychiatry and Neurology, Sobieskiego 9, 02-957 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"ref_1","unstructured":"GBD 2019 Diseases and Injuries Collaborators (2020). Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990\u20132019: A Systematic Analysis for the Global Burden of Disease Study 2019. Lancet, 396, 1204\u20131222."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global Prevalence and Burden of Depressive and Anxiety Disorders in 204 Countries and Territories in 2020 Due to the COVID-19 Pandemic","volume":"398","author":"Santomauro","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"GBD 2019 Mental Disorders Collaborators (2022). Global, Regional, and National Burden of 12 Mental Disorders in 204 Countries and Territories, 1990\u20132019: A Systematic Analysis for the Global Burden of Disease Study 2019. Lancet Psychiatr., 9, 137\u2013150.","DOI":"10.1016\/S2215-0366(21)00395-3"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jad.2014.05.043","article-title":"Bipolar Disorders Following Initial Depression: Modeling Predictive Clinical Factors","volume":"167","author":"Tondo","year":"2014","journal-title":"J. Affect. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 Guidelines for the Management of Patients with Bipolar Disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1192\/bjp.2018.257","article-title":"Treatment-Resistant and Multi-Therapy-Resistant Criteria for Bipolar Depression: Consensus Definition","volume":"214","author":"Berk","year":"2019","journal-title":"Br. J. Psychiatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bph.15753","article-title":"Novel Drug Developmental Strategies for Treatment-Resistant Depression","volume":"179","author":"Simon","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/mp.2018.2","article-title":"Deep Brain Stimulation for Treatment-Resistant Depression: An Integrative Review of Preclinical and Clinical Findings and Translational Implications","volume":"23","author":"Dandekar","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbi.2015.03.016","article-title":"Altered Fecal Microbiota Composition in Patients with Major Depressive Disorder","volume":"48","author":"Jiang","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9350","DOI":"10.12998\/wjcc.v9.i31.9350","article-title":"Major Depressive Disorder: Validated Treatments and Future Challenges","volume":"9","author":"Karrouri","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4605971","DOI":"10.1155\/2017\/4605971","article-title":"New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity","volume":"2017","author":"Huang","year":"2017","journal-title":"Neural Plast."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e1800027","DOI":"10.1002\/bies.201800027","article-title":"The Microbiota-Inflammasome Hypothesis of Major Depression","volume":"40","author":"Inserra","year":"2018","journal-title":"Bioessays"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2011.07.036","article-title":"Towards a Glutamate Hypothesis of Depression: An Emerging Frontier of Neuropsychopharmacology for Mood Disorders","volume":"62","author":"Sanacora","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jad.2016.12.059","article-title":"Medical Comorbidity in Bipolar Disorder: The Link with Metabolic-Inflammatory Systems","volume":"211","author":"SayuriYamagata","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"112802","DOI":"10.1016\/j.psychres.2020.112802","article-title":"Depression and Cardiovascular Disease: Shared Molecular Mechanisms and Clinical Implications","volume":"285","author":"Shao","year":"2020","journal-title":"Psychiatr. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fnmol.2020.00124","article-title":"The P2X7 Receptor: Central Hub of Brain Diseases","volume":"13","author":"Andrejew","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jad.2018.08.021","article-title":"Microglial Markers in the Frontal Cortex Are Related to Cognitive Dysfunctions in Major Depressive Disorder","volume":"241","author":"Li","year":"2018","journal-title":"J. Affect. Disord"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jad.2021.06.001","article-title":"Neuroinflammation in Major Depressive Disorder: A Review of PET Imaging Studies Examining the 18-KDa Translocator Protein","volume":"292","author":"Gritti","year":"2021","journal-title":"J. Affect. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1038\/s41380-020-00896-z","article-title":"Distinct Non-Inflammatory Signature of Microglia in Post-Mortem Brain Tissue of Patients with Major Depressive Disorder","volume":"26","author":"Snijders","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3389\/fpsyt.2022.863734","article-title":"Inflammatory Markers in Substance Use and Mood Disorders: A Neuroimaging Perspective","volume":"13","author":"Agarwal","year":"2022","journal-title":"Front. Psychiatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104922","DOI":"10.1016\/j.neubiorev.2022.104922","article-title":"Association between Diffusion Tensor Imaging, Inflammation and Immunological Alterations in Unipolar and Bipolar Depression: A Review","volume":"143","author":"Aronica","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jad.2022.12.162","article-title":"Structural and Functional MRI Correlates of Inflammation in Bipolar Disorder: A Systematic Review","volume":"325","author":"Saccaro","year":"2023","journal-title":"J. Affect. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbi.2019.06.015","article-title":"Markers of Central Inflammation in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Studies Examining Cerebrospinal Fluid, Positron Emission Tomography and Post-Mortem Brain Tissue","volume":"81","author":"Enache","year":"2019","journal-title":"Brain. Behav. Immun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41380-019-0448-7","article-title":"Postmortem Evidence of Brain Inflammatory Markers in Bipolar Disorder: A Systematic Review","volume":"25","author":"Giridharan","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1503\/jpn.150226","article-title":"Reduced Kynurenine Pathway Metabolism and Cytokine Expression in the Prefrontal Cortex of Depressed Individuals","volume":"41","author":"Clark","year":"2016","journal-title":"J. Psychiatr. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A Meta-Analysis of Blood Cytokine Network Alterations in Psychiatric Patients: Comparisons between Schizophrenia, Bipolar Disorder and Depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol. Psychiatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fpsyt.2019.00030","article-title":"Cytokine Research in Depression: Principles, Challenges, and Open Questions","volume":"10","author":"Himmerich","year":"2019","journal-title":"Front. Psychiatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bbi.2020.02.010","article-title":"Inflammatory Markers in Depression: A Meta-Analysis of Mean Differences and Variability in 5,166 Patients and 5,083 Controls","volume":"87","author":"Osimo","year":"2020","journal-title":"Brain. Behav. Immun"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pnpbp.2017.04.028","article-title":"Clinical Staging and Serum Cytokines in Bipolar Patients during Euthymia","volume":"77","author":"Bristot","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12929-021-00742-6","article-title":"Inflammatory Signaling Mechanisms in Bipolar Disorder","volume":"28","author":"Jones","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"691200","DOI":"10.3389\/fphar.2021.691200","article-title":"Comparative Efficacy and Acceptability of Anti-Inflammatory Agents on Major Depressive Disorder: A Network Meta-Analysis","volume":"12","author":"Hang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ng, Q.X., Ramamoorthy, K., Loke, W., Lee, M.W.L., Yeo, W.S., Lim, D.Y., and Sivalingam, V. (2019). Clinical Role of Aspirin in Mood Disorders: A Systematic Review. Brain Sci., 9.","DOI":"10.3390\/brainsci9110296"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fpsyt.2019.00605","article-title":"Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders","volume":"10","author":"Sethi","year":"2019","journal-title":"Front. Psychiatr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/NDT.S385117","article-title":"Anti-Inflammatory Treatment Efficacy in Major Depressive Disorder: A Systematic Review of Meta-Analyses","volume":"19","author":"Simon","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_35","unstructured":"Ghlichloo, I., and Gerriets, V. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kulesza, A., Paczek, L., and Burdzinska, A. (2023). The Role of COX-2 and PGE2 in the Regulation of Immunomodulation and Other Functions of Mesenchymal Stromal Cells. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020445"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/clc.22814","article-title":"Cardiovascular Safety of NSAIDs: Additional Insights after PRECISION and Point of View","volume":"40","author":"Pepine","year":"2017","journal-title":"Clin. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ehjcvp\/pvac015","article-title":"Cardiorenal Risk of Celecoxib Compared with Naproxen or Ibuprofen in Arthritis Patients: Insights from the PRECISION Trial","volume":"8","author":"Obeid","year":"2022","journal-title":"Eur. Hear. J. Cardiovasc. Pharmacother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s40501-022-00267-1","article-title":"Repurposing Anti-Inflammatory Agents for Mood Disorders: An Updated Review of Current Evidence","volume":"9","author":"Kittur","year":"2022","journal-title":"Curr. Treat. Options Psychiatr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7872","DOI":"10.12998\/wjcc.v10.i22.7872","article-title":"Effect of Celecoxib on Improving Depression: A Systematic Review and Meta-Analysis","volume":"10","author":"Wang","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/1871527317666181105162347","article-title":"Efficacy of Celecoxib Adjunct Treatment on Bipolar Disorder: Systematic Review and Meta-Analysis","volume":"18","author":"Bavaresco","year":"2019","journal-title":"CNS. Neurol. Disord. Drug Targets"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 Explanation and Elaboration: Updated Guidance and Exemplars for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_43","unstructured":"Higgins, J., and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions: Online Version 5.1.0. Cochrane. Colab., Available online: www.training.cochrane.org\/handbook."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_45","unstructured":"Sterne, J., Higgins, J., Sterne, J.A.C., Higgins, J.P.T., and Reeves, B.C. (2014, September 24). Development Group for ACROBAT-NRSI. A Cochrane Risk of Bias Assessment Tool: For Non-Randomized Studies of Interventions (ACROBAT-NRSI), Version 1.0.0. Available online: http:\/\/www.bristo."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-Bias VISualization (Robvis): An R Package and Shiny Web App for Visualizing Risk-of-Bias Assessments","volume":"12","author":"McGuinness","year":"2020","journal-title":"Res. Synth. Methods"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/1060028015592215","article-title":"Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial","volume":"49","author":"Mohammadinejad","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"ref_48","first-page":"w13880","article-title":"Effects of Celecoxib on Inflammatory Markers in Bipolar Patients Undergoing Electroconvulsive Therapy: A Placebo-Controlled, Double-Blind, Randomised Study","volume":"144","author":"Kargar","year":"2014","journal-title":"Swiss Med. Wkly."},{"key":"ref_49","first-page":"627","article-title":"Effects of Celecoxib on Electroconvulsive Therapy-Induced Cognitive Impairment in Patients with Major Depressive Disorder: A Pilot, Double-Blind, Placebo-Controlled Trial","volume":"57","author":"Banaha","year":"2019","journal-title":"Acta. Med. Iran."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jad.2012.03.033","article-title":"Effect of Celecoxib Add-on Treatment on Symptoms and Serum IL-6 Concentrations in Patients with Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Study","volume":"141","author":"Abbasi","year":"2012","journal-title":"J. Affect. Disord."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/da.20589","article-title":"Clinical Trial of Adjunctive Celecoxib Treatment in Patients with Major Depression: A Double Blind and Placebo Controlled Trial","volume":"26","author":"Akhondzadeh","year":"2009","journal-title":"Depress. Anxiety"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/sj.mp.4001805","article-title":"The Cyclooxygenase-2 Inhibitor Celecoxib Has Therapeutic Effects in Major Depression: Results of a Double-Blind, Randomized, Placebo Controlled, Add-on Pilot Study to Reboxetine","volume":"11","author":"Muller","year":"2006","journal-title":"Mol. Psychiatr."},{"key":"ref_53","first-page":"891","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial of Celecoxib Augmentation of Sertraline in Treatment of Drug-Naive Depressed Women: A Pilot Study","volume":"14","author":"Majd","year":"2015","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2021.07.092","article-title":"No Evidence for Clinical Efficacy of Adjunctive Celecoxib with Vortioxetine in the Treatment of Depression: A 6-Week Double-Blind Placebo Controlled Randomized Trial","volume":"53","author":"Baune","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"615261","DOI":"10.3389\/fpsyt.2021.615261","article-title":"Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline-Results from a Randomized Controlled Clinical Trial","volume":"12","author":"Simon","year":"2021","journal-title":"Front. Psychiatr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jad.2019.10.021","article-title":"Modulation of the Inflammatory Response Benefits Treatment-Resistant Bipolar Depression: A Randomized Clinical Trial","volume":"261","author":"Halaris","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hup.912","article-title":"Celecoxib as an Adjunct in the Treatment of Depressive or Mixed Episodes of Bipolar Disorder: A Double-Blind, Randomized, Placebo-Controlled Study","volume":"23","author":"Nery","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2215-0366(20)30138-3","article-title":"Minocycline and Celecoxib as Adjunctive Treatments for Bipolar Depression: A Multicentre, Factorial Design Randomised Controlled Trial","volume":"7","author":"Husain","year":"2020","journal-title":"Lancet Psychiatr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bdi.12324","article-title":"Celecoxib Adjunctive Therapy for Acute Bipolarmania: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"17","author":"Arabzadeh","year":"2015","journal-title":"Bipolar Disord."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1055\/s-0035-1559667","article-title":"Effect of Adjunctive Celecoxib on BDNF in Manic Patients Undergoing Electroconvulsive Therapy: A Randomized Double Blind Controlled Trial","volume":"48","author":"Kargar","year":"2015","journal-title":"PharmacoPsychiatr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2018.02.004","article-title":"Plasma C-Reactive Protein Levels in Bipolar Depression during Cyclooxygenase-2 Inhibitor Combination Treatment","volume":"102","author":"Edberg","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jad.2011.05.047","article-title":"Elevated Macrophage Migration Inhibitory Factor and Decreased Transforming Growth Factor-Beta Levels in Major Depression\u2014No Influence of Celecoxib Treatment","volume":"134","author":"Musil","year":"2011","journal-title":"J. Affect. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fpsyt.2017.00016","article-title":"High Kynurenine (a Tryptophan Metabolite) Predicts Remission in Patients with Major Depression to Add-on Treatment with Celecoxib","volume":"8","author":"Krause","year":"2017","journal-title":"Front. Psychiatr."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.npbr.2019.07.001","article-title":"Effects of Inflammation Modulation on Tryptophan and Kynurenine Pathway Regulation in Treatment Resistant Bipolar Depression","volume":"33","author":"Murata","year":"2019","journal-title":"Neurol. Psychiatr. Brain Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbi.2020.01.004","article-title":"Effects of Adjunctive Inflammatory Modulation on IL-1\u03b2 in Treatment Resistant Bipolar Depression","volume":"87","author":"Murata","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jpsychires.2020.06.010","article-title":"Plasma MCP-1 Levels in Bipolar Depression during Cyclooxygenase-2 Inhibitor Combination Treatment","volume":"129","author":"Edberg","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"100117","DOI":"10.1016\/j.jadr.2021.100117","article-title":"Elevated Salivary Cortisol Predicts Response to Adjunctive Immune Modulation in Treatment-Resistant Bipolar Depression","volume":"4","author":"Murata","year":"2021","journal-title":"J. Affect. Disord. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"112781","DOI":"10.1016\/j.psychres.2020.112781","article-title":"Vascular Endothelial Growth Factor in Bipolar Depression: A Potential Biomarker for Diagnosis and Treatment Outcome Prediction","volume":"284","author":"Castillo","year":"2020","journal-title":"Psychiatr. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.psychres.2017.05.029","article-title":"Efficacy and Safety of Celecoxib Monotherapy for Mild to Moderate Depression in Patients with Colorectal Cancer: A Randomized Double-Blind, Placebo Controlled Trial","volume":"255","author":"Alamdarsaravi","year":"2017","journal-title":"Psychiatr. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jcpt.12287","article-title":"Celecoxib for the Treatment of Mild-to-Moderate Depression Due to Acute Brucellosis: A Double-Blind, Placebo-Controlled, Randomized Trial","volume":"40","author":"Jafari","year":"2015","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.biopsych.2020.03.007","article-title":"Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder","volume":"88","author":"Attwells","year":"2020","journal-title":"Biol. Psychiatr."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000107420","article-title":"Effect of the COX-2 Inhibitor Celecoxib on Behavioural and Immune Changes in an Olfactory Bulbectomised Rat Model of Depression","volume":"14","author":"Myint","year":"2007","journal-title":"Neuroimmunomodulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2009.03.076","article-title":"Chronic Treatment with Celecoxib Reverses Chronic Unpredictable Stress-Induced Depressive-like Behavior via Reducing Cyclooxygenase-2 Expression in Rat Brain","volume":"612","author":"Guo","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"ref_74","first-page":"226","article-title":"Effect of COX-Inhibitors Attentuated LPS Induced Behavioural Alterations in Male Wistar Rats","volume":"5","author":"Prakash","year":"2013","journal-title":"J. Pharm. Sci. Res."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Maciel, I.S., Silva, R.B.M., Morrone, F.B., Calixto, J.B., and Campos, M.M. (2013). Synergistic Effects of Celecoxib and Bupropion in a Model of Chronic Inflammation-Related Depression in Mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077227"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s11064-014-1322-2","article-title":"Effect of a Selective Cyclooxygenase Type 2 Inhibitor Celecoxib on Depression Associated with Obesity in Mice: An Approach Using Behavioral Tests","volume":"39","author":"Kurhe","year":"2014","journal-title":"Neurochem. Res."},{"key":"ref_77","first-page":"S218","article-title":"Antidepressant-like Effect of Celecoxib Piroxicam in Rat Models of Depression","volume":"121","author":"Santiago","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_78","first-page":"596126","article-title":"Animal Models of Depression and Drug Delivery with Food as an Effective Dosing Method: Evidences from Studies with Celecoxib and Dicholine Succinate","volume":"2015","author":"Cline","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bbr.2015.07.015","article-title":"Interferon-Alpha Treatment Induces Depression-like Behaviour Accompanied by Elevated Hippocampal Quinolinic Acid Levels in Rats","volume":"293","author":"Fischer","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jad.2018.05.030","article-title":"Sub-Chronic Celecoxib Prevents Soluble Beta Amyloid-Induced Depressive-like Behaviour in Rats","volume":"238","author":"Morgese","year":"2018","journal-title":"J. Affect. Disord."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"107779","DOI":"10.1016\/j.neuropharm.2019.107779","article-title":"COX-2 Inhibition Rescues Depression-like Behaviors via Suppressing Glial Activation, Oxidative Stress and Neuronal Apoptosis in Rats","volume":"160","author":"Song","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"20190016","DOI":"10.1515\/jcim-2019-0016","article-title":"Celecoxib, Ibuprofen, and Indomethacin Alleviate Depression-like Behavior Induced by Interferon-Alfa in Mice","volume":"17","author":"Mesripour","year":"2020","journal-title":"J. Complement. Integr. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10251","DOI":"10.1111\/jcmm.15628","article-title":"Molecular and Behavioural Abnormalities in the FUS-Tg Mice Mimic Frontotemporal Lobar Degeneration: Effects of Old and New Anti-Inflammatory Therapies","volume":"24","author":"Babaevskaya","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"146846","DOI":"10.1016\/j.brainres.2020.146846","article-title":"Mefenamic Acid Can Attenuate Depressive Symptoms by Suppressing Microglia Activation Induced upon Chronic Stress","volume":"1740","author":"Feng","year":"2020","journal-title":"Brain Res."},{"key":"ref_85","first-page":"133","article-title":"The NSAIDs Ibuprofen and Celecoxib and the TNF-\u03b1 Blocker Etanercept Prevented Cyclosporine A-Induced Depression-Like Behavior in Mice","volume":"41","author":"Mesripour","year":"2021","journal-title":"Hacettepe. Univ. J. Fac. Pharm."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Strekalova, T., Pavlov, D., Trofimov, A., Anthony, D.C., Svistunov, A., Proshin, A., Umriukhin, A., Lyundup, A., Lesch, K.-P., and Cespuglio, R. (2022). Hippocampal Over-Expression of Cyclooxygenase-2 (COX-2) Is Associated with Susceptibility to Stress-Induced Anhedonia in Mice. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042061"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1523\/JNEUROSCI.3569-08.2009","article-title":"Increased Phospholipase A2 Activity and Inflammatory Response but Decreased Nerve Growth Factor Expression in the Olfactory Bulbectomized Rat Model of Depression: Effects of Chronic Ethyl-Eicosapentaenoate Treatment","volume":"29","author":"Song","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jad.2018.04.063","article-title":"Neither All Anti-Inflammatory Drugs nor All Doses Are Effective in Accelerating the Antidepressant-like Effect of Fluoxetine in an Animal Model of Depression","volume":"235","author":"Alboni","year":"2018","journal-title":"J. Affect. Disord."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pbb.2019.05.009","article-title":"Coadministration of Lithium and Celecoxib Attenuates the Behavioral Alterations and Inflammatory Processes Induced by Amphetamine in an Animal Model of Mania","volume":"183","author":"Valvassori","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41398-019-0637-9","article-title":"Coadministration of Lithium and Celecoxib Reverses Manic-like Behavior and Decreases Oxidative Stress in a Dopaminergic Model of Mania Induced in Rats","volume":"9","author":"Valvassori","year":"2019","journal-title":"Transl. Psychiatr."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.13712","article-title":"Inflammation in Psychiatric Disorders: What Comes First?","volume":"1437","author":"Bauer","year":"2019","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/hup.2401","article-title":"Celecoxib: A New Augmentation Strategy for Depressive Mood Episodes. A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials","volume":"29","author":"Faridhosseini","year":"2014","journal-title":"Hum. Psychopharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","article-title":"Augmentation Strategies for Treatment Resistant Major Depression: A Systematic Review and Network Meta-Analysis","volume":"302","author":"Joseph","year":"2022","journal-title":"J. Affect. Disord."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatr."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Dominiak, M., G\u0119dek, A., Sikorska, M., Mierzejewski, P., Wojnar, M., and Antosik-W\u00f3jci\u0144ska, A.Z. (2022). Acetylsalicylic Acid and Mood Disorders: A Systematic Review. Pharmaceuticals, 16.","DOI":"10.3390\/ph16010067"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jad.2016.01.015","article-title":"Long-Term Risk of Myocardial Infarction and Stroke in Bipolar I Disorder: A Population-Based Cohort Study","volume":"194","author":"Prieto","year":"2016","journal-title":"J. Affect. Disord."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/PSY.0000000000001017","article-title":"Association of Bipolar Disorder with Major Adverse Cardiovascular Events: A Population-Based Historical Cohort Study","volume":"84","author":"Foroughi","year":"2022","journal-title":"Psychosom. Med."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Lambert, A.M., Parretti, H.M., Pearce, E., Price, M.J., Riley, M., Ryan, R., Tyldesley-Marshall, N., Av\u015far, T.S., Matthewman, G., and Lee, A. (2022). Temporal Trends in Associations between Severe Mental Illness and Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1003960"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.amjmed.2017.06.028","article-title":"The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial","volume":"130","author":"Solomon","year":"2017","journal-title":"Am. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.21037\/apm-21-590","article-title":"Clinical Efficacy Evaluation and Prevention of Adverse Reactions in a Randomized Trial of a Combination of Three Drugs in the Treatment of Cancerous Pudendal Neuralgia","volume":"10","author":"Hou","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/pm\/pnaa230","article-title":"Meta-Analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis","volume":"22","author":"Huang","year":"2021","journal-title":"Pain Med."},{"key":"ref_102","first-page":"CD012095","article-title":"Celecoxib for Rheumatoid Arthritis","volume":"6","author":"Fidahic","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01616412.2020.1812805","article-title":"Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis","volume":"43","author":"Esmael","year":"2021","journal-title":"Neurol. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/CEJ.0000000000000594","article-title":"Progress in Cancer Mortality, Incidence, and Survival: A Global Overview","volume":"29","author":"Santucci","year":"2020","journal-title":"Eur. J. cancer. Prev. Off. J. Eur. Cancer. Prev. Organ."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global Cancer Incidence and Mortality Rates and Trends\u2014An Update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol Biomark. Prev."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jad.2012.03.025","article-title":"Anxiety and Depression after Cancer Diagnosis: Prevalence Rates by Cancer Type, Gender, and Age","volume":"141","author":"Linden","year":"2012","journal-title":"J. Affect. Disord."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/j.seminoncol.2020.08.003","article-title":"Depression in Women with a Diagnosis of Breast Cancer. Prevalence of Symptoms of Depression in Peruvian Women with Early Breast Cancer and Related Sociodemographic Factors","volume":"47","author":"Custodio","year":"2020","journal-title":"Semin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1017.E11","DOI":"10.1016\/j.amjmed.2013.02.037","article-title":"NSAIDs Are Associated with Lower Depression Scores in Patients with Osteoarthritis","volume":"126","author":"Iyengar","year":"2013","journal-title":"Am. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/18756190MTA4dOTMh0","article-title":"The Emerging Role of the Double-Edged Impact of Arachidonic Acid- Derived Eicosanoids in the Neuroinflammatory Background of Depression","volume":"19","author":"Regulska","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/PL00000287","article-title":"Effect of Rofecoxib on Nociception and the Serotonin System in the Rat Brain","volume":"51","author":"Sandrini","year":"2002","journal-title":"Inflamm. Res."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Ng, Q.X., Lim, Y.L., Yaow, C.Y.L., Ng, W.K., Thumboo, J., and Liew, T.M. (2023). Effect of Probiotic Supplementation on Gut Microbiota in Patients with Major Depressive Disorders: A Systematic Review. Nutrients, 15.","DOI":"10.3390\/nu15061351"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1067\/mcp.2003.14","article-title":"Isozyme-Specific Induction of Low-Dose Aspirin on Cytochrome P450 in Healthy Subjects","volume":"73","author":"Chen","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jad.2017.10.042","article-title":"Efficacy and Tolerability of Minocycline for Depression: A Systematic Review and Meta-Analysis of Clinical Trials","volume":"227","author":"Rosenblat","year":"2018","journal-title":"J. Affect. Disord."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1007\/s00213-020-05629-2","article-title":"N-Acetylcysteine as an Adjunctive Treatment for Bipolar Depression and Major Depressive Disorder: A Systematic Review and Meta-Analysis of Double-Blind, Randomized Placebo-Controlled Trials","volume":"237","author":"Kishi","year":"2020","journal-title":"Psychopharmacology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.18m12200","article-title":"A Double-Blind, Randomized, Placebo-Controlled Study of Aspirin and N-Acetylcysteine as Adjunctive Treatments for Bipolar Depression","volume":"80","author":"Bauer","year":"2018","journal-title":"J. Clin. Psychiatr."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/10\/3497\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:36:09Z","timestamp":1760124969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/10\/3497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":116,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["jcm12103497"],"URL":"https:\/\/doi.org\/10.3390\/jcm12103497","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]}}}